Epigenetic Regulation of Fatty Acid Amide Hydrolase in Alzheimer Disease
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Alzheimer disease (AD) is a progressive, degenerative and irreversible neurological disorder with few therapies available. In search for new potential targets, increasing evidence suggests a role for the endocannabinoid system (ECS) in the regulation of neurodegenerative processes. METHODS: We have studied the gene expression status and the epigenetic regulation of ECS components in peripheral blood mononuclear cells (PBMCs) of subjects with late-onset AD (LOAD) and age-matched controls (CT). RESULTS: We found an increase in fatty acid amide hydrolase (faah) gene expression in LOAD subjects (2.30 ± 0.48) when compared to CT (1.00 ± 0.14; *p<0.05) and no changes in the mRNA levels of any other gene of ECS elements. Consistently, we also observed in LOAD subjects an increase in FAAH protein levels (CT: 0.75 ± 0.04; LOAD: 1.11 ± 0.15; *p<0.05) and activity (pmol/min per mg protein CT: 103.80 ± 8.73; LOAD: 125.10 ± 4.00; *p<0.05), as well as a reduction in DNA methylation at faah gene promoter (CT: 55.90 ± 4.60%; LOAD: 41.20 ± 4.90%; *p<0.05). CONCLUSIONS: Present findings suggest the involvement of FAAH in the pathogenesis of AD, highlighting the importance of epigenetic mechanisms in enzyme regulation; they also point to FAAH as a new potential biomarker for AD in easily accessible peripheral cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kok, J. S., Berg, I. J., & Scherder, E. J. A. (2013) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000353441 · Cited by 20,589
Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS–ADRDA criteria
Dubois, B., Feldman, H. H., Jacova, C., DeKosky, S. T., Barberger-Gateau, P., Cummings, J., Delacourte, A., Galasko, D., Gauthier, S., Jicha, G., et al. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70178-3 · Cited by 4,411
Histone deacetylases (HDACs): characterization of the classical HDAC family
RUIJTER, A. J. M. D., GENNIP, A. H. V., CARON, H. N., KEMP, S., & KUILENBURG, A. B. P. V. (2003) · Biochemical Journal · doi:10.1042/bj20021321 · Cited by 3,114
The molecular logic of endocannabinoid signalling
Piomelli, D. (2003) · Nature Reviews Neuroscience · doi:10.1038/nrn1247 · Cited by 1,957 · cited 2×
“AEA, 2-AG and congeners, their target receptors and the respective metabolic enzymes form the ECS [5,8,9,10].”
BackgroundEpigenetic regulation in psychiatric disorders
Tsankova, N., Renthal, W., Kumar, A., & Nestler, E. J. (2007) · Nature reviews. Neuroscience · doi:10.1038/nrn2132 · Cited by 1,400 · cited 1×
“Gene expression in the nervous system is modulated by epigenetic processes which consist of mitotically heritable, but reversible, changes in gene accessibility that occur without a change in the genomic DNA sequence [28,29].”
BackgroundCravatt, B. F., Demarest, K., Patricelli, M. P., Bracey, M. H., Giang, D. K., Martin, B. R., & Lichtman, A. H. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.161191698 · Cited by 1,310
CB1 Cannabinoid Receptors and On-Demand Defense Against Excitotoxicity
Marsicano, G., Goodenough, S., Monory, K., Hermann, H., Eder, M., Cannich, A., Azad, S. C., Cascio, M. G., Gutiérrez, S. O., van der Stelt, M., et al. (2003) · Science · doi:10.1126/science.1088208 · Cited by 1,208 · cited 2×
“This hypothesis is also in line with the neuroprotective effect observed upon CB1 receptor stimulation [12], and with the role that ECS might have in pathological processes like amyloid protein accumulation in AD [3].”
BackgroundResultOccurrence of neuropathological changes and dementia of Alzheimer’s disease in Down’s syndrome
Wisniewski, K. E., Wisniewski, H. M., & Wen, G. Y. (1985) · Annals of Neurology · doi:10.1002/ana.410170310 · Cited by 1,159 · cited 1×
“Consistently with these results, an increase of both CB2 and FAAH expression was found in glial cells surrounding Ab plaques in tissue samples from subjects with Down syndrome [23], a condition that shares common pathways with AD [24].”
ResultIuvone, T., Esposito, G., Esposito, R., Santamaria, R., Di Rosa, M., & Izzo, A. A. (2004) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2003.02327.x · Cited by 361
D'Addario, C., Dell'Osso, B., Palazzo, M. C., Benatti, B., Lietti, L., Cattaneo, E., Galimberti, D., Fenoglio, C., Cortini, F., Scarpini, E., et al. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2012.10 · Cited by 192
Self-citation
Cited by
Cannabinoids and the expanded endocannabinoid system in neurological disorders
Cristino, L., Bisogno, T., & Di Marzo, V. (2020) · Nature Reviews Neurology · doi:10.1038/s41582-019-0284-z · Cited by 970
Metabolism of the Endocannabinoid Anandamide: Open Questions after 25 Years
Maccarrone, M. (2017) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2017.00166 · Cited by 172
“For instance, FAAH-1 activity and expression are up-regulated in Alzheimer’s disease patients (D’Addario et al., 2012), unlike any other ECS element analyzed (including CB1, CB2, and NAPE-PLD).”
BackgroundSelf-citationChiurchiù, V., van der Stelt, M., Centonze, D., & Maccarrone, M. (2018) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2017.10.007 · Cited by 140
“…of key genes involved in various neurotransmitter systems (D’Addario et al., 2013), and the evidence that FAAH is epigenetically regulated in AD patients (D’Addario et al., 2012), has opened a novel avenue to the possible design of specific epigenetic drugs targeting elements of the eCB system.”
Self-citationBlood DNA methylation as a potential biomarker of dementia: A systematic review
Fransquet, P. D., Lacaze, P., Saffery, R., McNeil, J., Woods, R., & Ryan, J. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2017.10.002 · Cited by 96
Natural sesquiterpen lactones as acetylcholinesterase inhibitors
HAJIMEHDIPOOR, H., MOSADDEGH, M., NAGHIBI, F., HAERI, A., & HAMZELOO-MOGHADAM, M. (2014) · Anais da Academia Brasileira de Ciências · doi:10.1590/0001-3765201420130005 · Cited by 22
Metadata
- Authors
- D'Addario, C., Di Francesco, A., Arosio, B., Gussago, C., Dell'Osso, B., Bari, M., Galimberti, D., Scarpini, E., Altamura, A. C., Mari, D., & Maccarrone, M.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2012-06-12
- Volume
- 7
- Issue
- 6
- Pages
- e39186
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W2036268594
- Cited by
- 87
- References
- 11
- FWCI
- 5.99
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Epigenetic Regulation of Fatty Acid Amide Hydrolase in Alzheimer Disease. https://app.cochat.ai/papers/10.1371/journal.pone.0039186
- The paper
- D'Addario, C., Di Francesco, A., Arosio, B., Gussago, C., Dell'Osso, B., Bari, M., Galimberti, D., Scarpini, E., Altamura, A. C., Mari, D., & Maccarrone, M. (2012). Epigenetic Regulation of Fatty Acid Amide Hydrolase in Alzheimer Disease. PLoS ONE. https://doi.org/10.1371/journal.pone.0039186
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.